1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
CorMedix Inc.

CorMedix Inc.

CRMD
CorMedix Inc.US flagNASDAQ Global Market
8.19
USD
+0.41
- -
642.52MMarket Cap
CorMedix Inc.
CRMD
(NASDAQ Global Market)

Recent

price

8.19

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
0.04
0.03
0.03
0.03
0.02
0.01
0.01
0.01
- -
- -
0.74
4.33
5.3
Revenue per Share
-5.76
-2.92
-1.48
-3.44
-4.79
-2.91
-3.25
-2.99
-1.51
-0.68
-0.77
-0.75
-0.74
-0.91
-0.3
2.26
2.4
Basic EPS, GAAP
-1.94
-2.76
-1
-1.32
-1.48
-2
-2.94
-2.61
-1.33
-0.62
-0.77
-0.6
-0.61
-0.76
-0.86
2.4
2.58
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-19.12
-18.78
-20.26
-20.16
-17.76
-15.05
-15.69
-13.79
-10.04
-8.09
-7.61
-6.52
-6.84
-6.32
-5.77
-2.45
-1.83
Book Value per Share
3.83
0.58
-0.15
-1.46
0.85
5.43
2.35
0.65
0.28
0.98
1.55
1.67
1.37
1.38
1.41
-0.05
0.51
Tangible Book Value per Share
2
2
2
3
4
6
8
11
18
24
29
38
40
51
59
72
76
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
43
312
400
Sales/Revenue/Turnover
- -
- -
- -
-245,646.93
-4,703.3
-7,925.56
-11,048.8
-9,997.39
-6,250.44
-7,416.31
-11,378.44
-15,417.51
-46,819.91
- -
-51.43
48.17
48.41
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
15
25
Depreciation Expense
-11
-7
-3
-9
-20
-18
-25
-33
-27
-16
-22
-28
-30
-46
-18
163
181
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2.16
Effective Tax Rate (%)
- -
- -
- -
-456,426.69
-10,806.25
-8,655.37
-10,996.46
-10,023.45
-6,242.4
-5,801.29
-9,207.7
-14,774.7
-45,409.9
- -
-41.24
52.31
45.25
Profit Margin (%)
7
1
-1
1
4
34
18
7
11
24
44
61
53
68
81
193
254
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
6
- -
1
1
1
1
- -
147
145
LT Debt
7
1
- -
-4
4
34
18
7
5
24
44
63
55
70
85
405
437
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
53.07
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-117.98
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
1
1
- -
LT Borrowings
145
145
145
LT Finance Leases
3
3
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
78
79
78
Market Capitalization
787
837
513

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
260
367
383
Cash, Cash Equivalents & STI
56
149
178
Accounts Receivable, Net
159
171
155
Inventories
29
30
31
Total Current Liabilities
134
174
129
Payables & Accruals
129
168
121
ST Debt
1
1
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
78.41%
91.3%
378.76%
Free Cash Flow
-24.17%
-68.18%
-440.59%
Net Income, GAAP
-93.53%
-196.27%
-1,009.4%
Sales/Revenue/Turnover
- -
- -
617.03%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
1
11
31
43
2025
39
40
104
129
312
2026
127
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.25
-0.25
-0.05
0.22
-0.3
2025
0.32
0.29
1.43
0.18
2.26
2026
0.49
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Tissue Regenix Group plc (TRX.L)
Celltrion, Inc. (068270.KS)
First Wave BioPharma, Inc. (FWBI)
U.S. Stem Cell, Inc. (USRM)
Graf Acquisition Corp. IV (GFOR-WT)
Creative Medical Technology Holdings, Inc. (CELZ)
Business
CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening infectious and inflammatory diseases, primarily targets hospital and dialysis settings in the United States with expanding international presence. Founded in 2006 and headquartered in Berkeley Heights, New Jersey, the company offers DefenCath (taurolidine and heparin catheter lock solution), the first and only FDA-approved antimicrobial therapy to reduce catheter-related bloodstream infections in adult hemodialysis patients via central venous catheters; following its August 2025 acquisition of Melinta Therapeutics LLC, CorMedix also commercializes an expanded portfolio of anti-infective products including MINOCIN (minocycline for infections), REZZAYO (rezafungin for candidemia and invasive candidiasis), VABOMERE (meropenem and vaborbactam for urinary tract and complicated intra-abdominal infections), ORBACTIV (oritavancin for acute bacterial skin and skin structure infections), BAXDELA (delafloxacin for skin infections and community-acquired bacterial pneumonia), KIMYRSA (oritavancin for bloodstream and skin infections), and TOPROL-XL (metoprolol succinate for cardiovascular conditions). The company conducts ongoing clinical studies for DefenCath in total parenteral nutrition, pediatric, and oncology patient populations, while REZZAYO advances in a Phase III trial for prophylaxis of invasive fungal infections in allogeneic blood and marrow transplant patients, with topline results expected in Q2 2026. Recent developments include the transformative September 2025 completion of the Melinta Therapeutics acquisition, which diversifies the product portfolio, raises pro forma 2025 revenue guidance to $325-350 million, projects annual synergies of $35-45 million, and introduces enhanced leadership in hospital acute care; in October 2025, DefenCath earned Innovative Technology Designation from Vizient for its clinical impact on infection prevention; third-quarter 2025 results reported $104.3 million in net revenue and $130.8 million pro forma, driven by commercial launches and market penetration.

Company News

APIChatGPT

  • zacks.com

    Is CRMD Stock a Buy Now After Strong Growth and New Risks?

  • zacks.com

    CRMD's Growth Story Expands Beyond DefenCath Into New Trends

  • zacks.com

    CRMD Stock Outlook as DefenCath and Rezzayo Expand Growth Path

  • globenewswire.com

    U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent Litigation

  • seekingalpha.com

    CorMedix: Bleak Short-Term Outlook, But Significantly Undervalued For The Long Run

  • marketbeat.com

    CorMedix Eyes REZZAYO Expansion as DefenCath Reimbursement Shift Looms

  • zacks.com

    CRMD Q1 Earnings Beat on DefenCath Momentum, Guidance Raised

  • globenewswire.com

    Cormedix Therapeutics to Participate in two Upcoming Investor Conferences

  • benzinga.com

    CorMedix Stock Jumps As DefenCath Fuels Q1 Beat, 2026 Outlook Raised

  • seekingalpha.com

    CorMedix Inc. (CRMD) Q1 2026 Earnings Call Transcript

  • marketbeat.com

    CorMedix Q1 Earnings Call Highlights

  • zacks.com

    CorMedix (CRMD) Q1 Earnings and Revenues Beat Estimates

  • globenewswire.com

    Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

  • zacks.com

    CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

  • globenewswire.com

    CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026

  • benzinga.com

    CorMedix Eyes $2 Billion Market With Encouraging Data From Fungal Infection Study

  • globenewswire.com

    CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients

  • seekingalpha.com

    CorMedix: A Shrinking Core And No Proven Second Engine

  • globenewswire.com

    CorMedix to Participate in Needham Virtual Healthcare Conference

  • defenseworld.net

    Phocas Financial Corp. Takes $1.99 Million Position in CorMedix Inc $CRMD